Altimmune to Present at Upcoming Investor and Scientific Conferences

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences:

• Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 29-December 2, 2021Webcast available now

• 5th Annual NASH Summit 2021November 30, 20219:00 am Eastern Time

• 4th Annual Evercore ISI HealthCONx ConferenceDecember 2, 202110:55 am Eastern Time

Presentation materials, including webcast links to the Piper Sandler and Evercore ISI presentations, will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Will BrownChief Financial OfficerPhone: 240-654-1450[email protected]

You May Also Be Interested In

• Senteon Earns Honorable Mention in Black Hat USA 2026 Startup Spotlight Competition
• Trial Boutique Martin Walker PC Founders Named to 2027 Best Lawyers in America
• Greenheart Gold Commences Initial Diamond Drill Program at the Tosso Creek Project, Suriname, Targeting Below Recent Trench Results That Include Intervals of 56.0 M @ 0.97 g/t Au and 7.0 M @ 4.57 g/t